Ginkgetin / RadioS Cancer Research Results

Ginkgetin — a naturally occurring biflavonoid, specifically a dimethylated derivative of amentoflavone, found in Ginkgo biloba and several other plants. It is chemically and pharmacologically distinct from generic Ginkgo biloba extract, EGb 761, ginkgolides, bilobalide, and ginkgolic acids. Ginkgetin has predominantly preclinical anticancer evidence, with reported effects on ferroptosis, apoptosis, cell-cycle arrest, proliferation, invasion, angiogenesis, and chemotherapy sensitivity. Major signaling systems reported to be modulated include NRF2/HO-1, JAK/STAT, PI3K/AKT/GSK-3β, MAPK, Wnt/β-catenin, and TFEB-associated ferroptotic signaling. It should be treated as an isolated natural-product constituent rather than as evidence for the pharmacological effects of ordinary Ginkgo supplementation.

Ginkgetin — a naturally occurring biflavonoid, specifically a 3′→8″-linked biflavone and dimethylated derivative of amentoflavone, with the synonym 7,4′-dimethylamentoflavone. It is a small-molecule plant polyphenol rather than a Ginkgo extract and is commonly abbreviated GK. Ginkgetin occurs in Ginkgo biloba leaves and several other plant species. It is chemically and pharmacologically distinct from generic Ginkgo biloba extract, EGb 761, ginkgolides, bilobalide, and ginkgolic acids. Current evidence is predominantly preclinical and supports treating Ginkgetin as a separate isolated natural-product constituent rather than extrapolating its effects to ordinary Ginkgo supplementation.

Primary mechanisms (ranked):

1. Induction of Ferroptosis through TFEB activation and TFEB–TRIM25-dependent GPX4 ubiquitination and lysosomal degradation, producing loss of GPX4-mediated lipid-peroxide defense.
2. Disruption of NRF2/HO-1 antioxidant signaling with SLC7A11/GPX4 suppression, GSH depletion, Fe²⁺ accumulation, lipid peroxidation, and increased oxidative stress, particularly during cisplatin treatment.
3. Suppression of oncogenic JAK2/STAT3 signaling, including SHP-1/PTEN-associated inhibition of STAT3 phosphorylation, proliferation, survival, and tumorigenic signaling.
4. Suppression of metastatic EMT through AKT/GSK-3β/Snail and Wnt/β-catenin signaling, reducing migration and invasion in experimental lung-cancer models.
5. Induction of apoptotic signaling through mitochondrial dysfunction, Bax/Bcl-2 modulation, caspase activation, PARP cleavage, and context-dependent MAPK activation.
6. ROS/H₂O₂-mediated cytotoxicity, with rapid oxidative stress contributing to caspase-dependent apoptosis in susceptible cancer cells.
7. Cell-cycle inhibition, including G2/M arrest and suppression of proliferative Wnt target genes such as cyclin D1 and survivin.
8. Anti-angiogenic activity through inhibition of VEGF/VEGFR2-associated AKT, eNOS, ERK, MMP-2, and MMP-9 signaling in experimental vascular models.
9. Chemosensitization, particularly increased cisplatin responsiveness in experimental lung and cisplatin-resistant cervical cancer through ferroptotic and redox mechanisms.

Bioavailability / PK relevance: Ginkgetin is highly lipophilic and poorly water-soluble, creating an important oral-delivery limitation. Human pharmacokinetic data for isolated Ginkgetin are essentially absent, and no validated human anticancer plasma target or therapeutic dose has been established. Experimental formulation work, including nanomicelles, is being investigated specifically to improve its systemic exposure. Ginkgetin is also a potent in-vitro inhibitor of UGT1A1, creating a potential drug-interaction concern if pharmacologically relevant systemic concentrations can be achieved.

In-vitro vs systemic exposure relevance: Most anticancer studies use isolated Ginkgetin at micromolar concentrations, commonly over prolonged exposures. These concentrations cannot presently be assumed achievable through oral Ginkgo products or conventional Ginkgetin administration because human Cmax data are unavailable and oral bioavailability is poorly characterized. Thus, direct translation of micromolar cell-culture effects to dietary or supplemental Ginkgo exposure is weak.

Clinical evidence status: Preclinical only. Evidence includes cancer-cell studies and multiple mouse xenograft or metastasis models, including lung, breast, prostate, medulloblastoma, and cervical-cancer systems. No established human anticancer trials, approved anticancer indication, validated clinical dose, or demonstrated human therapeutic efficacy was identified. FDA substance registration provides a chemical identifier but does not constitute regulatory approval.

Ginkgetin Cancer-Relevant Mechanisms

TSF: P: 0–30 min     R: 30 min–3 hr     G: >3 hr